What is the recommended treatment for Trichomoniasis vaginalis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Trichomoniasis Vaginalis

The preferred treatment for Trichomoniasis vaginalis is metronidazole 500 mg orally twice daily for 7 days, which achieves cure rates of approximately 90-95%. 1

First-Line Treatment Options

  • Metronidazole 500 mg orally twice daily for 7 days is the preferred regimen recommended by the Centers for Disease Control and Prevention 1
  • An alternative regimen is metronidazole 2 g orally in a single dose, which may be preferred when medication adherence is a concern 2, 1
  • Tinidazole 2 g orally in a single dose is also effective with cure rates comparable to metronidazole (95% vs 97.5% respectively) 3, 4

Management of Sex Partners

  • All sexual partners should be treated simultaneously to prevent reinfection 2, 1
  • Patients should avoid sexual intercourse until both they and their partners have completed treatment and are asymptomatic 1, 5
  • Treating asymptomatic partners is essential as T. vaginalis is a sexually transmitted disease that can cause reinfection if partners remain untreated 6

Treatment Failure Management

  • For first treatment failure, re-treat with metronidazole 500 mg twice daily for 7 days 2, 1
  • For repeated failure, administer metronidazole 2 g once daily for 3-5 days 2, 5
  • For metronidazole-resistant cases, a combination of high-dose tinidazole (2 g twice daily for 14 days) with a broad-spectrum antibiotic and clotrimazole pessaries has shown 90% efficacy in patients who attended follow-up 7

Important Clinical Considerations

  • Metronidazole gel is NOT recommended for trichomoniasis treatment despite its approval for bacterial vaginosis, as its efficacy is considerably lower (<50%) compared to oral metronidazole 2, 8
  • Routine follow-up is unnecessary for patients who become asymptomatic after treatment 2, 1
  • Accurate diagnosis before treatment is important, using methods such as wet mount microscopy, culture, or nucleic acid amplification tests 1

Special Populations

Pregnancy

  • Pregnant women can be treated with metronidazole 2 g orally in a single dose 2, 1
  • Treatment is particularly important as trichomoniasis has been associated with adverse pregnancy outcomes, including premature rupture of membranes, preterm delivery, and low birthweight 2, 9

HIV Infection

  • Patients with HIV infection should receive the same treatment regimen as HIV-negative individuals 2, 5

Metronidazole Allergy

  • Patients with immediate-type allergy to metronidazole can be managed by desensitization 2, 1
  • Topical therapy with drugs other than nitroimidazoles can be attempted in allergic patients, but cure rates are low (<50%) 2

Pitfalls and Caveats

  • Failure to treat sexual partners is a common cause of recurrent infection 2, 6
  • Metronidazole and tinidazole are the only effective drug class for trichomoniasis; alternatives have significantly lower efficacy 2, 8
  • Screening and treatment should be considered before any reproductive tract surgery and during pregnancy to prevent complications 9
  • Patients should be advised to avoid alcohol during treatment with metronidazole or tinidazole and for at least 24-72 hours afterward to prevent disulfiram-like reactions 1

References

Guideline

Treatment of Trichomonas vaginalis Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Single dose treatment of trichomoniasis.

The Journal of international medical research, 1982

Guideline

Treatment of Trichomoniasis Vaginal Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Trichomonas vaginalis: a reemerging pathogen.

Clinical obstetrics and gynecology, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.